Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Azacitidine and Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

Study:

A Phase I Study of 5-Azacitidine in Combination With Interferon-Alfa 2B in Unresectable or Metastatic Melanoma and Renal Cell Carcinoma

Rationale:

Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Interferon alfa-2b may interfere with the growth of tumor cells. Giving azacitadine together with interferon alfa-2b may kill more tumor cells.

Purpose:

This phase I trial is studying the side effects and best dose of interferon alfa-2b when given together with azacitidine in treating patients with stage III or stage IV melanoma or stage IV kidney cancer that cannot be removed by surgery.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Kidney Cancer
Melanoma (Skin)
Biological: recombinant interferon alfa-2b
Drug: azacitidine
Phase 1

Verified by Yale University November, 2006

Sponsored by: Yale University
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00217542

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Mario Sznol, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site